Feierl Gebhard, Jelovcan Sandra
Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Austria.
Wien Klin Wochenschr. 2009;121(3-4):103-7. doi: 10.1007/s00508-008-1129-8.
Campylobacter species are among the most commonly identified causative agents of acute bacterial gastroenteritis in humans worldwide. In Austria, campylobacteriosis has been a notifiable disease since 1996 and its incidence has increased continuously over the past years. Improvement of notification has led to an important increase in knowledge of the epidemiology of this disease in Austria. In addition to existing programs monitoring food safety, implementation of a national surveillance program to monitor antimicrobial resistance and the prevalence of campylobacter in food animals allows continuous surveillance of trends in antimicrobial susceptibility patterns in humans, animals and food, as well as a more comprehensive evaluation of the occurrence of campylobacter in the relevant reservoirs of human infection. Such data make it possible to identify the most important areas for intervention and launch of control strategies. As in other countries around the world, antimicrobial resistance of campylobacter from human, animal and food origin, particularly resistance to fluoroquinolones, is of public health concern in Austria. The magnitude of global trade and foreign travel requires EU-wide and worldwide implementation of control strategies to fight campylobacteriosis.
弯曲杆菌属是全球范围内人类急性细菌性肠胃炎最常见的致病原之一。在奥地利，自1996年起弯曲杆菌病成为法定报告传染病，且其发病率在过去几年持续上升。报告工作的改进使得奥地利对该疾病流行病学的了解有了显著增加。除了现有的食品安全监测项目外，实施一项全国性监测项目以监测抗菌药物耐药性及食用动物中弯曲杆菌的流行情况，能够持续监测人类、动物和食品中抗菌药物敏感性模式的趋势，以及对人类感染相关宿主中弯曲杆菌的发生情况进行更全面的评估。这些数据有助于确定最重要的干预领域并启动控制策略。与世界其他国家一样，来自人类、动物和食品源的弯曲杆菌的抗菌药物耐药性，尤其是对氟喹诺酮类药物的耐药性，在奥地利是一个公共卫生问题。全球贸易和境外旅行的规模要求在欧盟范围内乃至全球实施控制策略以对抗弯曲杆菌病。
